![Gitasha Chand](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gitasha Chand
Technik-/Wissenschafts-/F&E-Leiter bei RADIOPHARM THERANOSTICS LIMITED
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Hong-Hoi Ting | M | - |
NanoMab Technology Ltd.
![]() NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | 8 Jahre |
Thomas Tulip | M | 71 | 3 Jahre | |
Riccardo Canevari | M | - | 3 Jahre | |
Ian Turner | M | - | - | |
Levente Meszaros | M | - |
NanoMab Technology Ltd.
![]() NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | 2 Jahre |
Hester Larkin | F | - | 2 Jahre | |
Henry Ho | M | - |
NanoMab Technology Ltd.
![]() NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | 8 Jahre |
Paul Hopper | M | 68 | 3 Jahre | |
Vittorio Puppo | M | - | 2 Jahre | |
Scot Harper | M | 67 | 3 Jahre | |
Leila Alland | M | 61 | 2 Jahre | |
Nathan Jong | M | - | - | |
David Mozley | M | - | - | |
Sherin Al-Safadi | M | - | 1 Jahre | |
Antje Wegener | F | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Michael Baker | M | - | 3 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Australien | 14 | 87,50% |
China | 3 | 18,75% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Gitasha Chand
- Persönliches Netzwerk